Member Info for MALTBY2002

Further statistical evidence to support saliva based testing. Definitely worth a read

Whilst most value is likely to be added through a successful LFT antigen test, don’t underestimate the impact on updates on our neutralising therapies, sewage collaboration with SKIN and MWG both of whom had good gains last week and of course BAMS. News on all 3 could well come before any flow test results and should at the very least keep the shorters on their toes.

Great news but it still refers to an anti body test. Any explanations?

Thought he said nigh on impossible but might be wrong

Key question is up to 1 billion dollars was not mentioned in the original RNS so how accurate is the Business Weekly article? Fantastic news if it is accurate

RD, As I am sure you are aware BBN has tweeted a series of posts today all of which highlight the huge potential of AVCT post COVID 19 and specifically the manner in which monies made from the LFDs will speed up the development of the suite of diagnostic and treatment trials waiting to be delivered. AVCT is not a one trick pony as the derampers would want us to believe

My understanding is that any potential manufacturer of the LFD antigen test would have to send off batches to be clinically validated so Medusa saying the branding on the test may differ shouldn’t create a problem.

5.1 interesting saying they are currently experiencing a high volume of demand for the product.

Just trying to get a bit of clarity from the excitement following the updated Medusa web site:
- the test published on this site is clearly an antibody test as confirmed by their late inclusion of the word immunity and to that extent the late flurry of buys in the last 15 minutes was based on a false premise.
- Medusa’s web site makes clear they will not market antigen tests that compete with AVCT and there will be no need for Al to RNS on Monday any clarification as initially suggested.
- Plenty of bad press on Medusa that I do not subscribe to. They didn’t jump the gun as it is not AVCT‘s test and they have some very experienced professionals in their team with a lot more retail experience than the people who are criticising them.
- There is clearly a lot going on behind the scenes re infrastructure, manufacturing partners etc indicating the extent of the global market that is potentially available to AVCT.
- In the meantime the clinical validation process continues, the excitement builds and we are a day nearer to the news w are all hoping to wake up to.

The stand out quote from a CEO who is not known for overstating

As part of the application process you are asked to state your broker and it will be to this account where your allotted shares will be sent

According to a person leading the research into a vaccine quoted in the ST today there is only a 1 in 3 chance of ever finding a vaccine. AVCT will not only have the best diagnostic tests available but also a potential neutralising treatment

Fantastic post Badeli. They are probably the same people who leave their litter lying around

Far too much concentration on the UK market. We are in the midst of a global epidemic and the UK is a very small part of that market.

Was the original aim to pay the remaining 65% for EUR 10.85?

According to the CEO of SKIN the collaboration has now progressed to them using the virus provided by the PHE so maybe an update on this may occur shortly as well

Yes this has been updated recently and is a further indication that things are going to plan and the blockbuster news we are all hoping/expecting is not too far away. Even without an RNS tomorrow the lockdown in Spain will provide further evidence this virus is going nowhere and a rapid LFD will be a key element in preventing 14 day quarantines and further disruption to the T and T business

Which UK company is capable of 8 million tests of saliva based pregnancy type tests? Interesting

I disagree the fact that the LFD has now been included in the Condor programme would suggest the test works and the optimisation process is complete

Well that’s the problem of access to live samples sorted and clearly the optimisation process also complete. Boom indeed

Good article. Don’t underestimate the potential revenues of not only BAMS but also the wastewater collaboration announced on Monday and described in this article